Dear Shareholders, On behalf of the board ( Board ) of directors ( Directors ) of Austar Lifesciences Limited ( Company ), I am pleased to present the annual report of the Company and its subsidiaries (collectively as the Group or AUSTAR ) for the year ended 31 December 2020 ( Year ). The year 2020 has been a challenging year for any individual, company and organization under the impact of the COVID-19 pandemic and its consequential policies. From a global perspective, the pandemic has not been slowing down even though China s pandemic conditions had become far stable and under extraordinary control. Under such conditions, the Group has been reacting, responding and acting during such extraordinary moments. Our colleagues could never have believed they were able to deliver our critical utilities and bioprocess systems to our COVID-19 vaccine manufacturer clients within 3 months from order to completion of installation and commissioning with construc
Nifty to tumble over 180 points on fresh lockdown announcements
April 19, 2021
×
Though Covid-19-related situation is worrisome, IMD and Skymet predicting normal monsoon for the country augurs well for the market
Indian markets are expected to open sharply lower on Monday, as fresh lockdowns have been announced by various governments following spread of the Covid-19 pandemic. The SGX Nifty, which currently rules at 14,463 at the Singapore Stock Exchange, indicates at least a 180 points gap-down opening for Nifty futures, which on Friday closed at 14,645.
Analysts fear the recovery in the Indian economy could falter on fresh lockdowns announced by various State governments. States such as Maharashtra, Gujarat, Tamil Nadu and Delhi have announced fresh lockdowns and night curfews recently.
Glenmark Life Sciences Ltd files DRHP with SEBI for IPO equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Curaleaf Completes Acquisition of EMMAC and Secures US$130 Million Investment from a Single Strategic Institutional Investor
News provided by
Share this article
Share this article
EMMAC brings vertically integrated operations in Europe with a presence in key medical cannabis markets, including the UK, Germany, Italy, Spain, and Portugal
Strategic investor to fund cash portion of acquisition and Curaleaf s growth initiatives in Europe
WAKEFIELD, Mass., April 7, 2021 /PRNewswire/
Curaleaf Holdings, Inc. (CSE: CURA /OTCQX: CURLF) ( Curaleaf or the Company ), a leading international provider of consumer products in cannabis has successfully completed the previously announced acquisition of EMMAC Life Sciences Limited ( EMMAC ), the largest vertically integrated independent cannabis company in Europe, for base consideration of approximately US$50 million in cash and 17.5 million shares of Curaleaf, with additional consideration to be paid based upon the successful achievement